Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS<br />
<strong>Company</strong>/Organization Date Area of<br />
Collaboration<br />
Terms of Agreement<br />
MorphoSys 2004 Drug discovery 3-yr, $40m agreement (as well as<br />
potential milestones/royalties) to use the<br />
German company’s HuCal Gold antibody<br />
technology with MorphoSys providing<br />
antibodies to range of Novartis targets<br />
Novartis has option to take technology<br />
in-house for additional payment and<br />
option to extend to 5 yrs. Novartis made a<br />
milestone payment in August 2005.<br />
Collaboration extended until 2011.<br />
Myogen 2003 Cardiovascular<br />
research<br />
Novartis Institutes for Biomedical<br />
Research and Myogen collaborating on<br />
discovery of cardiovascular candidates<br />
that Novartis will gain exclusive rights to<br />
license in return for 3-yrs of funding. In<br />
2005, the collaboration was expanded to<br />
include Myogen’s histone deacetylase<br />
inhibitor (HDACi) program. Collaboration<br />
extended for two years in 2006.<br />
Vernalis 2003 Oncology Collaboration to investigate inhibitors of a<br />
Hsp90 implicated in the progression of a<br />
range of cancers. Extended for 3 years in<br />
2004 with STG5m equity investment (7m<br />
shares/4.6% stake) and $1.5m signing<br />
fee. Novartis to fund all R&D.<br />
Cytos 2003 Immunodrugs 2-yr licensing agreement of immunodrugs<br />
in field of Alzheimer’s disease triggering<br />
payment, license fees and milestones to<br />
Cytos. Already working on RA as part of<br />
2001 agreement but alliance in allergies<br />
discontinued and also working on<br />
therapeutic vaccines in CNS disorders.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 137
Change language